The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances.
Amphetamine
Ketamine
New psychoactive substances
Opioids
Stress-addiction axis
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
17
5
2021
medline:
29
10
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
Organic cation transporters 1-3 (OCT1-3, SLC22A1-3) and the plasma membrane monoamine transporter (PMAT, SLC29A4) play a major role in maintaining monoaminergic equilibrium in the central nervous system. With many psychoactive substances interacting with OCT1-3 and PMAT, a growing literature focuses on characterizing their properties via in vitro and in vivo studies. In vitro studies mainly aim at characterizing compounds as inhibitors or substrates of murine, rat, and human isoforms. The preponderance of studies has put emphasis on phenylalkylamine derivatives, but ketamine and opioids have also been investigated. Studies employing in vivo (knockout) models mostly concentrate on the interaction of psychoactive substances and OCT3, with an emphasis on stress and addiction, pharmacokinetics, and sensitization to psychoactive drugs. The results highlight the importance of OCT3 in the mechanism of action of psychoactive compounds. Concerning in vivo studies, a veritable research gap concerning OCT1, 2, and PMAT exists. This review provides an overview and summary of research conducted in this field of research.
Identifiants
pubmed: 33993413
doi: 10.1007/164_2021_469
doi:
Substances chimiques
Cations
0
Organic Cation Transport Proteins
0
Organic Cation Transporter 1
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-214Subventions
Organisme : Austrian Science Fund FWF
ID : DOC 33
Pays : Austria
Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Amphoux A, Vialou V, Drescher E, Bruss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bonisch H, Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50(8):941–952. https://doi.org/10.1016/j.neuropharm.2006.01.005
doi: 10.1016/j.neuropharm.2006.01.005
pubmed: 16581093
Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T, Ozaki N (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res 30(10):1644–1649. https://doi.org/10.1111/j.1530-0277.2006.00215.x
doi: 10.1111/j.1530-0277.2006.00215.x
pubmed: 17010131
Baganz N, Horton R, Martin K, Holmes A, Daws LC (2010) Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. J Neurosci 30(45):15185–15195. https://doi.org/10.1523/jneurosci.2740-10.2010
doi: 10.1523/jneurosci.2740-10.2010
pubmed: 21068324
pmcid: 3064500
Barr JL, Forster GL (2011) Serotonergic neurotransmission in the ventral hippocampus is enhanced by corticosterone and altered by chronic amphetamine treatment. Neuroscience 182:105–114. https://doi.org/10.1016/j.neuroscience.2011.03.020
doi: 10.1016/j.neuroscience.2011.03.020
pubmed: 21420472
Barr JL, Scholl JL, Solanki RR, Watt MJ, Lowry CA, Renner KJ, Forster GL (2013) Influence of chronic amphetamine treatment and acute withdrawal on serotonin synthesis and clearance mechanisms in the rat ventral hippocampus. Eur J Neurosci 37(3):479–490. https://doi.org/10.1111/ejn.12050
doi: 10.1111/ejn.12050
pubmed: 23157166
Castells LD, Muralter M, Gratacos NN, Puster B, Berzosa X, Estrada R, Niello M, Bhat S, Pubill D, Camarasa J, Sitte H, Escubedo E (2020) Arnau RlLp. https://doi.org/10.22541/au.158921571.14272689
Chaves C, Campanelli F, Chapy H, Gomez-Zepeda D, Glacial F, Smirnova M, Taghi M, Pallud J, Perriere N, Decleves X, Menet MC, Cisternino S (2020) An interspecies molecular and functional study of organic cation transporters at the blood-brain barrier: from rodents to humans. Pharmaceutics 12(4). https://doi.org/10.3390/pharmaceutics12040308
Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM (2010) Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 20(11):687–699. https://doi.org/10.1097/FPC.0b013e32833fe789
doi: 10.1097/FPC.0b013e32833fe789
pubmed: 20859243
pmcid: 2976715
Chiba S, Ikawa T, Takeshita H, Kanno S, Nagai T, Takada M, Mukai T, Wempe MF (2013) Human organic cation transporter 2 (hOCT2): inhibitor studies using S2-hOCT2 cells. Toxicology 310:98–103. https://doi.org/10.1016/j.tox.2013.06.001
doi: 10.1016/j.tox.2013.06.001
pubmed: 23770354
Clauss NJ, Koek W, Daws LC (2021) Role of organic cation transporter 3 in the locomotor sensitizing effects and rewarding properties of amphetamine in male and female mice. FASEB J 35
Courousse T, Gautron S (2015) Role of organic cation transporters (OCTs) in the brain. Pharmacol Ther 146:94–103. https://doi.org/10.1016/j.pharmthera.2014.09.008
doi: 10.1016/j.pharmthera.2014.09.008
pubmed: 25251364
Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106(19):8043–8048. https://doi.org/10.1073/pnas.0900358106
doi: 10.1073/pnas.0900358106
pubmed: 19416912
pmcid: 2683105
Fraser-Spears R, Krause-Heuer AM, Basiouny M, Mayer FP, Manishimwe R, Wyatt NA, Dobrowolski JC, Roberts MP, Greguric I, Kumar N, Koek W, Sitte HH, Callaghan PD, Fraser BH, Daws LC (2019) Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter. Eur J Pharmacol 842:351–364. https://doi.org/10.1016/j.ejphar.2018.10.028
doi: 10.1016/j.ejphar.2018.10.028
pubmed: 30473490
Fujimoto Y, Kitaichi K, Nakayama H, Ito Y, Takagi K, Takagi K, Hasegawa T (2007) The pharmacokinetic properties of methamphetamine in rats with previous repeated exposure to methamphetamine: the differences between long-Evans and Wistar rats. Exp Anim 56(2):119–129. https://doi.org/10.1538/expanim.56.119
doi: 10.1538/expanim.56.119
pubmed: 17460357
Gasser PJ (2019) Roles for the uptake2 transporter OCT3 in regulation of dopaminergic neurotransmission and behavior. Neurochem Int 123:46–49. https://doi.org/10.1016/j.neuint.2018.07.008
doi: 10.1016/j.neuint.2018.07.008
pubmed: 30055194
Graf EN, Wheeler RA, Baker DA, Ebben AL, Hill JE, McReynolds JR, Robble MA, Vranjkovic O, Wheeler DS, Mantsch JR, Gasser PJ (2013) Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci 33(29):11800–11810. https://doi.org/10.1523/JNEUROSCI.1969-13.2013
doi: 10.1523/JNEUROSCI.1969-13.2013
pubmed: 23864669
pmcid: 3713722
Ho HT, Pan Y, Cui Z, Duan H, Swaan PW, Wang J (2011) Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter. J Pharmacol Exp Ther 339(2):376–385. https://doi.org/10.1124/jpet.111.184036
doi: 10.1124/jpet.111.184036
pubmed: 21816955
pmcid: 3199987
Holleran KM, Rose JH, Fordahl SC, Benton KC, Rohr KE, Gasser PJ, Jones SR (2020) Organic cation transporter 3 and the dopamine transporter differentially regulate catecholamine uptake in the basolateral amygdala and nucleus accumbens. Eur J Neurosci 52(11):4546–4562. https://doi.org/10.1111/ejn.14927
doi: 10.1111/ejn.14927
pubmed: 32725894
Hosoya K-I, Tachikawa M (2011) Roles of organic anion/cation transporters at the blood–brain and blood–cerebrospinal fluid barriers involving uremic toxins. Clin Exp Nephrol 15(4):478–485. https://doi.org/10.1007/s10157-011-0460-y
doi: 10.1007/s10157-011-0460-y
pubmed: 21611756
Ilic M, Holy M, Jaentsch K, Liechti ME, Lubec G, Baumann MH, Sitte HH, Luethi D (2020) Cell-based radiotracer binding and uptake inhibition assays: a comparison of in vitro methods to assess the potency of drugs that target monoamine transporters. Front Pharmacol 11(673). https://doi.org/10.3389/fphar.2020.00673
Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH (2003) Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23(21):7902–7908. https://doi.org/10.1128/mcb.23.21.7902-7908.2003
doi: 10.1128/mcb.23.21.7902-7908.2003
pubmed: 14560032
pmcid: 207626
Keiser M, Hasan M, Oswald S (2018) Affinity of ketamine to clinically relevant transporters. Mol Pharm 15(1):326–331. https://doi.org/10.1021/acs.molpharmaceut.7b00627
doi: 10.1021/acs.molpharmaceut.7b00627
pubmed: 29191019
Keller T, Gorboulev V, Mueller TD, Dötsch V, Bernhard F, Koepsell H (2019) Rat organic cation transporter 1 contains three binding sites for substrate 1-methyl-4-phenylpyridinium per monomer. Mol Pharmacol 95(2):169–182. https://doi.org/10.1124/mol.118.113498
doi: 10.1124/mol.118.113498
pubmed: 30409791
Kido Y, Matsson P, Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54(13):4548–4558. https://doi.org/10.1021/jm2001629
doi: 10.1021/jm2001629
pubmed: 21599003
pmcid: 3257218
Kitaichi K, Morishita Y, Doi Y, Ueyama J, Matsushima M, Zhao Y-L, Takagi K, Hasegawa T (2003) Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. Eur J Pharmacol 464(1):39–48. https://doi.org/10.1016/s0014-2999(03)01321-9
Kitaichi K, Fukuda M, Nakayama H, Aoyama N, Ito Y, Fujimoto Y, Takagi K, Takagi K, Hasegawa T (2005) Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci Lett 382(1-2):195–200. https://doi.org/10.1016/j.neulet.2005.03.014
doi: 10.1016/j.neulet.2005.03.014
pubmed: 15911148
Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Asp Med 34(2-3):413–435. https://doi.org/10.1016/j.mam.2012.10.010
doi: 10.1016/j.mam.2012.10.010
Koepsell H (2020) Organic cation transporters in health and disease. Pharmacol Rev 72(1):253–319. https://doi.org/10.1124/pr.118.015578
doi: 10.1124/pr.118.015578
pubmed: 31852803
Koepsell H, Schmitt BM, Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36–90. https://doi.org/10.1007/s10254-003-0017-x
doi: 10.1007/s10254-003-0017-x
pubmed: 12827517
Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24(7):1227–1251. https://doi.org/10.1007/s11095-007-9254-z
doi: 10.1007/s11095-007-9254-z
pubmed: 17473959
Kousik SM, Napier TC, Carvey PM (2012) The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol 3:121. https://doi.org/10.3389/fphar.2012.00121
doi: 10.3389/fphar.2012.00121
pubmed: 22754527
pmcid: 3386512
Lin C-J, Tai Y, Huang M-T, Tsai Y-F, Hsu H-J, Tzen K-Y, Liou H-H (2010) Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem 114(3):717–727. https://doi.org/10.1111/j.1471-4159.2010.06801.x
doi: 10.1111/j.1471-4159.2010.06801.x
pubmed: 20477935
Liu HC, Goldenberg A, Chen Y, Lun C, Wu W, Bush KT, Balac N, Rodriguez P, Abagyan R, Nigam SK (2016) Molecular properties of drugs interacting with SLC22 transporters OAT1, OAT3, OCT1, and OCT2: a machine-learning approach. J Pharmacol Exp Ther 359(1):215–229. https://doi.org/10.1124/jpet.116.232660
doi: 10.1124/jpet.116.232660
pubmed: 27488918
pmcid: 5034704
Maier J, Mayer FP, Brandt SD, Sitte HH (2018) DARK classics in chemical neuroscience: Aminorex analogues. ACS Chem Neurosci 9(10):2484–2502. https://doi.org/10.1021/acschemneuro.8b00415
doi: 10.1021/acschemneuro.8b00415
pubmed: 30269490
Maier J, Rauter L, Rudin D, Niello M, Holy M, Schmid D, Wilson J, Blough BE, Gannon BM, Murnane KS, Sitte HH (2021) α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenonesand uptake1 and uptake2 monoamine transporters. Neuropharmacology 190:108570. https://doi.org/10.1016/j.neuropharm.2021.108570
Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, Holle SK, Sindic A, Dobrivojevic M, Pavenstadt H, Ciarimboli G (2014) The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch 466(3):517–527. https://doi.org/10.1007/s00424-013-1335-8
doi: 10.1007/s00424-013-1335-8
pubmed: 23982114
Mayer FP, Schmid D, Owens WA, Gould GG, Apuschkin M, Kudlacek O, Salzer I, Boehm S, Chiba P, Williams PH, Wu HH, Gether U, Koek W, Daws LC, Sitte HH (2018) An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology 43(12):2408–2417. https://doi.org/10.1038/s41386-018-0053-5
doi: 10.1038/s41386-018-0053-5
pubmed: 29773909
pmcid: 6180071
Mayer FP, Schmid D, Holy M, Daws LC, Sitte HH (2019) "Polytox" synthetic cathinone abuse: a potential role for organic cation transporter 3 in combined cathinone-induced efflux. Neurochem Int 123:7–12. https://doi.org/10.1016/j.neuint.2018.09.008
doi: 10.1016/j.neuint.2018.09.008
pubmed: 30248432
McReynolds JR, Taylor A, Vranjkovic O, Ambrosius T, Derricks O, Nino B, Kurtoglu B, Wheeler RA, Baker DA, Gasser PJ, Mantsch JR (2017) Corticosterone potentiation of cocaine-induced reinstatement of conditioned place preference in mice is mediated by blockade of the organic cation transporter 3. Neuropsychopharmacology 42(3):757–765. https://doi.org/10.1038/npp.2016.187
doi: 10.1038/npp.2016.187
pubmed: 27604564
Mofo Mato EP, Guewo-Fokeng M, Essop MF, Owira PMO (2018) Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: a systematic review. Medicine 97(27):e11349–e11349. https://doi.org/10.1097/MD.0000000000011349
doi: 10.1097/MD.0000000000011349
pubmed: 29979413
pmcid: 6076123
Nakayama H, Kitaichi K, Ito Y, Hashimoto K, Takagi K, Yokoi T, Takagi K, Ozaki N, Yamamoto T, Hasegawa T (2007) The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats. Brain Res 1184:260–269. https://doi.org/10.1016/j.brainres.2007.09.072
doi: 10.1016/j.brainres.2007.09.072
pubmed: 17988657
Niello M, Gradisch R, Loland CJ, Stockner T, Sitte HH (2020) Allosteric modulation of neurotransmitter transporters as a therapeutic strategy. Trends Pharmacol Sci 41(7):446–463. https://doi.org/10.1016/j.tips.2020.04.006
doi: 10.1016/j.tips.2020.04.006
pubmed: 32471654
pmcid: 7610661
Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1–19. https://doi.org/10.1016/j.drugalcdep.2014.12.005
doi: 10.1016/j.drugalcdep.2014.12.005
pubmed: 25548026
Sala-Rabanal M, Li DC, Dake GR, Kurata HT, Inyushin M, Skatchkov SN, Nichols CG (2013) Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3. Mol Pharm 10(4):1450–1458. https://doi.org/10.1021/mp400024d
doi: 10.1021/mp400024d
pubmed: 23458604
pmcid: 3632321
Sekhar GN, Georgian AR, Sanderson L, Vizcay-Barrena G, Brown RC, Muresan P, Fleck RA, Thomas SA (2017) Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB). PLoS One 12(3):e0173474–e0173474. https://doi.org/10.1371/journal.pone.0173474
doi: 10.1371/journal.pone.0173474
pubmed: 28362799
pmcid: 5376088
Sekhar GN, Fleckney AL, Boyanova ST, Rupawala H, Lo R, Wang H, Farag DB, Rahman KM, Broadstock M, Reeves S, Thomas SA (2019) Region-specific blood–brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease. Fluids Barriers CNS 16(1):38. https://doi.org/10.1186/s12987-019-0158-1
doi: 10.1186/s12987-019-0158-1
pubmed: 31842924
pmcid: 6915870
Shirasaka Y, Lee N, Duan H, Ho H, Pak J, Wang J (2017) Interspecies comparison of the functional characteristics of plasma membrane monoamine transporter (PMAT) between human, rat and mouse. J Chem Neuroanat 83-84:99–106. https://doi.org/10.1016/j.jchemneu.2016.09.006
doi: 10.1016/j.jchemneu.2016.09.006
pubmed: 27641077
Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36(1):41–50. https://doi.org/10.1016/j.tips.2014.11.006
doi: 10.1016/j.tips.2014.11.006
pubmed: 25542076
Solanki RR, Scholl JL, Watt MJ, Renner KJ, Forster GL (2016) Amphetamine withdrawal differentially increases the expression of organic cation transporter 3 and serotonin transporter in limbic brain regions. J Exp Neurosci 10:93–100. https://doi.org/10.4137/JEN.S40231
doi: 10.4137/JEN.S40231
pubmed: 27478387
pmcid: 4957605
Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmoller J (2013) Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 86(5):666–678. https://doi.org/10.1016/j.bcp.2013.06.019
doi: 10.1016/j.bcp.2013.06.019
pubmed: 23835420
Vialou V, Balasse L, Dumas S, Giros B, Gautron S (2007) Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144(2):616–622. https://doi.org/10.1016/j.neuroscience.2006.09.058
doi: 10.1016/j.neuroscience.2006.09.058
pubmed: 17110048
Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106(3):1471–1482. https://doi.org/10.1111/j.1471-4159.2008.05506.x
doi: 10.1111/j.1471-4159.2008.05506.x
pubmed: 18513366
Wagner DJ, Sager JE, Duan H, Isoherranen N, Wang J (2017) Interaction and transport of methamphetamine and its primary metabolites by organic cation and multidrug and toxin extrusion transporters. Drug Metab Dispos 45(7):770–778. https://doi.org/10.1124/dmd.116.074708
doi: 10.1124/dmd.116.074708
pubmed: 28428365
pmcid: 5478906
Wagner DJ, Shireman LM, Ahn S, Shen DD, Wang J (2018) Disposition of methamphetamine and major metabolites in mice: role of organic cation transporter 3 in tissue-selective accumulation of Para-Hydroxymethamphetamine. Drug Metab Dispos 46(9):1277–1284. https://doi.org/10.1124/dmd.118.082131
doi: 10.1124/dmd.118.082131
pubmed: 29915156
pmcid: 6081671
Wang J (2016) The plasma membrane monoamine transporter (PMAT): structure, function, and role in organic cation disposition. Clin Pharmacol Ther 100(5):489–499. https://doi.org/10.1002/cpt.442
doi: 10.1002/cpt.442
pubmed: 27506881
Wheeler DS, Ebben AL, Kurtoglu B, Lovell ME, Bohn AT, Jasek IA, Baker DA, Mantsch JR, Gasser PJ, Wheeler RA (2017) Corticosterone regulates both naturally occurring and cocaine-induced dopamine signaling by selectively decreasing dopamine uptake. Eur J Neurosci 46(10):2638–2646. https://doi.org/10.1111/ejn.13730
doi: 10.1111/ejn.13730
pubmed: 28965353
pmcid: 5704943
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V (1998) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273(49):32776–32786. https://doi.org/10.1074/jbc.273.49.32776
doi: 10.1074/jbc.273.49.32776
pubmed: 9830022
Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AF, Grundemann D, Schomig E, Lesch KP, Gerlach M, Reif A (2009) Decreased anxiety in mice lacking the organic cation transporter 3. J Neural Transm (Vienna) 116(6):689–697. https://doi.org/10.1007/s00702-009-0205-1
doi: 10.1007/s00702-009-0205-1
Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66(17):8847–8857. https://doi.org/10.1158/0008-5472.Can-06-0769
doi: 10.1158/0008-5472.Can-06-0769
pubmed: 16951202
pmcid: 2775093
Zhu HJ, Appel DI, Grundemann D, Markowitz JS (2010) Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem 114(1):142–149. https://doi.org/10.1111/j.1471-4159.2010.06738.x
doi: 10.1111/j.1471-4159.2010.06738.x
pubmed: 20402963
pmcid: 3775896